Form4insider filings, from the source

SEC Form 4 · accession 0001193805-15-001062

ANTARES PHARMA, INC. · ATRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owners
DEERFIELD MANAGEMENT CO
10% Owner · Other
Deerfield Mgmt L.P.
10% Owner · Other
DEERFIELD PARTNERS, LP
10% Owner · Other
James E Flynn
10% Owner · Other
Period of report
Jun 24, 2015
Accepted (ET)
Jun 26, 2015 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Jun 24, 2015S17,427$2.2892D3,619,518IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 24, 2015S52,494$2.2892D9,027,951IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 24, 2015S41,245$2.2892D7,093,392IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 24, 2015S12,344$2.30D3,607,174IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 24, 2015S37,181$2.30D8,990,770IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 24, 2015S29,214$2.30D7,064,178IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 24, 2015S11,477$2.3364D3,595,697IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 24, 2015S34,572$2.3364D8,956,198IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 24, 2015S27,164$2.3364D7,037,014IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 25, 2015S11,444$2.25D3,584,253IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 25, 2015S34,471$2.25D8,921,727IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 25, 2015S27,085$2.25D7,009,929IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 25, 2015S16,021$2.25D3,568,232IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 25, 2015S48,260$2.25D8,873,467IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 25, 2015S37,919$2.25D6,972,010IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 26, 2015S16,308$2.2508D3,551,924IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 26, 2015S49,124$2.2508D8,824,343IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 26, 2015S38,598$2.2508D6,933,412IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 26, 2015S33,627$2.2378D3,518,297IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 26, 2015S101,291$2.2378D8,723,052IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 26, 2015S79,586$2.2378D6,853,826IThrough Deerfield Partners, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Avalanche Biotechnologies, Inc. filed with the Securities and Exchange Commission on July 30, 2014 by Deerfield Mgmt III, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., Deerfield Special Situations International Master Fund, L.P., Deerfield Private Design Fund III, L.P. and James E. Flynn.